These issues, along with the variability in clinical variables, highlight the necessity of a prospective study that integrates diverse data, including clinical, radiological, and pathological information with PD-L1 IHC, to ensure a more comprehensive and precise validation of BC-GS. This evidence concerns the gene CD274 and breast cancer.